

Celgene 2006 Fact Sheet


PROFILE

Celgene Corporation, as a leader in global biotechnology, has built an integrated discovery, development and commercialization platform for drug and cell-based therapies that enables the company to continue to develop value within its therapeutic franchise areas of cancer and inflammatory diseases. This target-to-therapeutic platform integrates both small molecule and cell-based and spans the critical functions required to generate a large and diverse pipeline of innovative next generation drugs and cell therapies that address the source of the disease and not just the symptoms.

BUILDING ON SUCCESS

Celgene is delivering the promise of science to patients and their families facing extraordinary challenges with cancer and inflammatory disease through innovative next generation therapies. Driving commercial success and profitability are marketed products, which include REVLIMID®, THALOMID®, ALKERAN®, FOCALIN™ and FOCALIN XR™, cellular and tissue therapeutics, as well as the Ritalin® family of drugs.

REVENUE, R&D, & EPS



NEWS EVENTS

Celgene reported record 3rd quarter revenue and operating profits

Celgene announced total revenue was a record \$224.8 million for the quarter ended September 30, 2006, an increase of 89.1% over the same period in 2005 driven by REVLIMID® net sales of \$101.3 million, and THALOMID® net sales of \$108.4 million, an increase of 9.3% year-over-year. Alkeran® net sales for the third quarter were \$12.2 million in 2006 compared to \$13.9 million in 2005. Revenue from Focalin™ and the Ritalin® family of drugs totaled \$17.9 million for the quarter compared to \$10.7 million over the same period last year.

REVLIMID

- In June, the U.S. Food and Drug Administration (FDA) granted approval of REVLIMID (lenalidomide) in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy.
- Previously, in December, the FDA granted approval of REVLIMID for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q chromosome abnormality with or without additional cytogenetic abnormalities. For both multiple myeloma and MDS, REVLIMID will be available via specialty pharmacies through an education and prescribing safety program developed by Celgene called REvAssistSM.
- In June, data from two Phase III trials presented at the ASCO cancer conference evaluated REVLIMID plus dexamethasone in more than 700 previously treated myeloma patients at nearly 100 clinical sites worldwide. The updated clinical data from the pivotal North American Phase III trial (MM-009) reported overall survival ($p < 0.0001$) in addition to median time to disease progression ($p < 0.0001$) in patients receiving lenalidomide plus dexamethasone compared to patients receiving dexamethasone plus placebo. The updated clinical data from the pivotal International Phase III trial (MM-010) reported overall survival ($p = 0.03$). As of June 2006, median overall survival in the International trials in patients treated with lenalidomide plus dexamethasone has not been reached as compared to 20.6 months with dexamethasone plus placebo.
- In April, Celgene International Sàrl announced that the EMEA has accepted the Company's Marketing Authorization Application (MAA) for Lenalidomide – Celgene Europe. The application is based on clinical data from Phase III special protocol assessments trial, evaluating lenalidomide plus dexamethasone in multiple myeloma patients who have received at least one prior therapy.

THALOMID

- In May, the FDA granted accelerated approval to a supplemental new drug application (sNDA) for THALOMID (thalidomide) in combination with dexamethasone (dex) for the treatment of newly diagnosed multiple myeloma. THALOMID is available through the THALOMID Education and Prescribing Safety System program, S.T.E.P.S.®.
- At a plenary session at the American Society of Clinical Oncology (ASCO) cancer conference in June, updated clinical data from a phase III study in France demonstrated that median overall survival for patients on melphalan and prednisone plus thalidomide (MPT) was significantly longer (54 months) than patients on melphalan and prednisone alone (32 months) or stem cell transplant (38.6 months). In a separate oral presentation comparing thalidomide plus dex to dex alone, the median overall survival and median time to disease progression have not been reached in the thal/dex arm of the ongoing phase III study.

CORPORATE

- In May, Celgene announced that Chairman and Chief Executive Officer, John W. Jackson retired as CEO on May 1st. Mr. Jackson was re-elected as Chairman of the Board of Directors at the Company's annual meeting on June 15, 2006. On May 1st, Sol J. Barer assumed responsibility as the Company's Chief Executive Officer, and Robert J. Hugin assumed Dr. Barer's role as President and Chief Operating Officer.



PRODUCT PIPELINE

IMiDs®:

		Pre-clinical	Phase I	Phase II	Phase III	Regulatory Filing and Approval / *FDA Registered	
REVLIMID®:	MDS deletion 5Q (US)	[Progress bar]					
REVLIMID®:	Multiple Myeloma (US)	[Progress bar]					
REVLIMID®:	MDS deletion 5Q (EMEA)	[Progress bar]					
REVLIMID®:	Multiple Myeloma (EMEA)	[Progress bar]					
REVLIMID®:	MDS deletion 5Q (SWISS)	[Progress bar]					
REVLIMID®:	MDS	[Progress bar]					
REVLIMID®:	CLL	[Progress bar]					
REVLIMID®:	NHL	[Progress bar]					
REVLIMID®:	Solid Tumors	[Progress bar]					
CC-4047:	Sickle Cell Anemia	[Progress bar]					
CC-4047:	Myelofibrosis	[Progress bar]					
CC-4047:	Solid Tumors	[Progress bar]					
CC-11006:	Inflammatory/Immunological	[Progress bar]					
CC-10015:	Inflammatory	[Progress bar]					

THALOMID®:

ENL	[Progress bar]
Multiple Myeloma	[Progress bar]

ALKERAN®:

Multiple Myeloma/ Ovarian Cancer	[Progress bar]
-------------------------------------	----------------

Ritalin® /FOCALIN™:

FOCALIN:	ADHD	[Progress bar]
Ritalin LA®:	ADHD	[Progress bar]
FOCALIN XR™:	ADHD	[Progress bar]
FOCALIN:	Cancer Fatigue	[Progress bar]

Anti-Inflammatory:

CC-10004:	Psoriasis	[Progress bar]
CC-11050:	Inflammatory	[Progress bar]

Benzopyranes:

CC-8490:	Cancer	[Progress bar]
CC-113:	Cancer	[Progress bar]

Kinase Inhibitors:

JNK 401:	Cancer/Inflammatory	[Progress bar]
JNK 359:	Ischemia/Reperfusion	[Progress bar]
JNK 930:	Fibrotic Diseases	[Progress bar]

Ligase Inhibitors:

E2 Ligase Inhibitor:	Cancer	[Progress bar]
----------------------	--------	----------------

Stem Cells and Tissue Products:

Lifebank USA: Private Stem Cell Banking	[Progress bar]
Cord Blood Cells: Sickle Cell Anemia	[Progress bar]
BIOVANCE and Acelagraf™*	[Progress bar]

INVESTOR CONTACT INFORMATION

Robert J. Hugin
President and COO
Email: rhugin@celgene.com

Brian Gill
Senior Director of IR/PR
Email: bgill@celgene.com

CELGENE EXECUTIVE OFFICERS

Sol J. Barer, Ph.D.
Chief Executive Officer

Robert J. Hugin
President and Chief Operating Officer

ANALYST COVERAGE

Argus Research
Bank of America
Bear Stearns & Company
Citigroup Smith Barney
Friedman, Billings, Ramsey
JMP Securities LLC
JP Morgan Chase & Company
Lazard Capital Markets
Leerink Swan
Lehman Brothers
Merrill Lynch & Co.
Morgan Stanley
Piper Jaffray
Prudential Securities
R.W. Baird
Rodman & Renshaw
Thomas Weisel Partners

INVESTMENT CONSIDERATIONS

- Profitable and accelerating revenue growth supporting development of multiple clinical compounds across several high potential programs
- Lead clinical candidate REVLIMID offers near-term transforming potential as new innovative approach in treating cancer and inflammatory diseases
- Cutting edge research in cellular signaling technology delivering next generation therapies with potential to change standard of care
- Strong, evolving intellectual property estate supporting a broad, deep, unencumbered proprietary pipeline, in strategic programs, addressing large commercial opportunities
- Strong financial resources with close to \$758 million in cash & marketable securities positioned to support long-term growth strategy
- Effective senior management team experienced in successful execution of corporate strategies

The products represented as in development and found in the product pipeline are intended for investors and members of the media to provide general information on Celgene. This information is not represented to be a complete description and is subject to change without notice. Celgene Corporation may from time to time update this information but does not warrant that will take place at any particular time nor assume any obligation to update this information.